1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. PIRAMAL PHARMA LTD.
Piramal Pharma Ltd.
NSE: PPLPHARMA | BSE: 543635

Piramal Pharma Live Share Price Today, Share Analysis and Chart

Expensive Rocket
aboutPiramal Pharma Ltd. (PPL) is a global pharmaceutical entity providing end-to-end drug development and manufacturing solutions. The company operates through a diversified model across three main verticals: Contract Development and Manufacturing Organi... Read More
US FDA InspectionsANDA Approvals
Ask AI about Piramal Pharma
238.918.13(3.52%)

New 52W High today

28.4M
NSE+BSE Volume

High volume today

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
67.0 / 100
Expensive RocketThese stocks have good momentum, but are expensive with average financialsView SimilarEmbed DVM
Analyst Price Target
-

25

S

5

W

6

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

11Positive11Negative

50.0%Pass in checklist

045
55
100

Check P/E Buy Sell Zone

This stock has negative PE

Piramal Pharma Stock Price Analysis

Day Price Range

3.5% 1 Day return
238.9 (LTP)
225.8240
LowHigh

Week Price Range

25.0% 1 Week return
238.9 (LTP)
188.5240
LowHigh

Month Price Range

14.3% 1 Month return
238.9 (LTP)
185240
LowHigh

52 Week Price Range

18.3% 1 Year return
238.9 (LTP)
132.3240
LowHigh
View full Price History/Seasonality

Piramal Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Piramal Pharma's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
-2.5
AVG. ESTIMATE
1.6
LOW ESTIMATE
0.9
HIGH ESTIMATE
2.4
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 166.7% in FY27

Consensus Recommendation

11 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 11 analysts for Piramal Pharma is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Piramal Pharma Technical Analysis

Piramal Pharma EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day223.4
10 Day213.3
12 Day211.3
20 Day207.5
26 Day206.5
50 Day203.9
100 Day196.7
200 Day189.3

Piramal Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202625.3%
Week19.7%
Month24.4%

Piramal Pharma Active Candlesticks

Engulfing Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Piramal Pharma Resistance and Support

234.91
Pivot
First Resistance244
Second Resistance249.1
Third Resistance258.2
First Support229.8
Second Support220.7
Third Support215.6
Day RSI73.2
Day MACD4.7
Day MFI94.3
Day MACD Signal Line-0.4

Piramal Pharma Beta

1 Month0.7
1 Year1.1
3 Month0.9
3 Year0.9

Piramal Pharma Price Change Analysis

↑14.3%
Over 1 Month
LowHigh
185.0240
↑21.5%
Over 3 Months
LowHigh
185.0240
↑49.2%
Over 6 Months
LowHigh
156.1240
↑18.3%
Over 1 Year
LowHigh
132.3240
All Technicals →

Piramal Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
The Sri Krishna Trust (Through Its Trustee Mr. Ajay G Piramal And Dr. (Mrs.) Swati A. Piramal)Promoter352,891,42026.5 %
East Bridge Capital Master Fund I LtdFii26,638,4222 %
Ca Alchemy InvestmentsPublic238,663,70017.9 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap FundDii75,248,9945.7 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Piramal Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell20 Feb 2025219.886,856,958NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase20 Feb 2025219.706,856,958NSE
EAST BRIDGE CAPITAL MASTER FUND LIMITEDBlockSell31 Oct 2023102.8033,643,099BSE
EAST BRIDGE CAPITAL MASTER FUND I LIMITEDBlockPurchase31 Oct 2023102.8033,643,099BSE
EAST BRIDGE CAPITAL MASTER FUND I LIMITEDBulkPurchase31 Oct 2023102.8033,643,099BSE
EAST BRIDGE CAPITAL MASTER FUND LIMITEDBulkSell31 Oct 2023102.8033,643,099BSE
CAISSE DE DEPOT ET PLACEMENT DU QUEBECBulkSell16 Jun 202394.4810,570,466NSE
THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDBulkPurchase16 Jun 202394.716,202,912NSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell03 Nov 2022166.954,050,700BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase03 Nov 2022166.954,050,700BSE
All deals
All insider trades

Piramal Pharma Corporate Actions

Piramal Pharma Dividend history and yield

Piramal Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Piramal Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
116 Jul 2025
0.14FINAL16 Jul 2025Equity Share
212 Jul 2024
0.11FINAL12 Jul 2024Equity Share

Piramal Pharma Board Meetings

Piramal Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
127 Oct 2026
Quarterly Results-
229 Jul 2026
Quarterly Results-
328 Apr 2026
Audited Results-
428 Jan 2026
Quarterly Results-
505 Nov 2025
Quarterly Results-

Piramal Pharma Rights issue

Piramal Pharma rights issue history, along with record, ex-rights dates, and rights ratios.

#Ex-Date
RatioFace ValuePremiumRecord Date
102 Aug 2023
5.0:46.0107102 Aug 2023
All Corporate Actions

Piramal Pharma Research Reports

Piramal Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
128 Oct 2026ICICI Securities Limited
Target
290230.78Buy25.66%3.52%pdf
227 Oct 2026Motilal Oswal
Target
270232.8Buy15.98%2.62%pdf
330 Jul 2026ICICI Securities Limited245196.72Buy24.54%21.45%pdf
429 Jul 2026Motilal Oswal
Target
230196.72Buy16.92%21.45%pdf
529 Jul 2026ICICI Direct
Target
240196.72Buy22%21.45%pdf
All Reports of Piramal

Piramal Pharma Corporate Filings

Piramal Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
31 Oct 2026
Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
PDF
30 Oct 2026
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015
PDF
30 Oct 2026
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed details of Earning call Transcript held on 28th October 2026.
PDF
28 Oct 2026
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026.
PDF
28 Oct 2026
Q2FY27 Quarterly Result Announced for Piramal Pharma Ltd.
Pharmaceuticals company Piramal Pharma announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: Consolidated Revenue from Operations reached Rs 2,617.06 crore in Q2FY27, indicating a 28.05% YoY increase from Rs 2,043.72 crore in Q2FY26 and a 15.29% QoQ growth from Rs 2,269.92 crore in Q1FY27. For H1FY27, Revenue from Operations stood at Rs 4,886.98 crore, which is a 22.87% YoY expansion compared to Rs 3,977.44 crore in H1FY26. Total Income: Consolidated Total Income was recorded at Rs 2,652.99 crore in Q2FY27, up 25.77% YoY compared to Rs 2,109.32 crore in Q2FY26 and higher by 12.45% QoQ from Rs 2,359.33 crore in Q1FY27. For H1FY27, Total Income reached Rs 5,012.32 crore, registering a 22.21% YoY increase over Rs 4,101.44 crore in H1FY26. Profit Before Tax (PBT): PBT stood at Rs 81.63 crore in Q2FY27, showcasing a complete turnaround YoY from a loss before tax of Rs 46.18 crore in Q2FY26, and a strong reversal QoQ from a loss before tax of Rs 7.46 crore in Q1FY27. For H1FY27, PBT came in at Rs 74.18 crore, turning around from a loss before tax of Rs 125.20 crore in H1FY26. Profit After Tax (PAT): PAT achieved profitability at Rs 5.03 crore in Q2FY27, reversing YoY from a net loss after tax of Rs 99.22 crore in Q2FY26, and turning around QoQ from a net loss after tax of Rs 69.38 crore in Q1FY27. For H1FY27, net loss reduced significantly by 64.43% YoY to a loss of Rs 64.35 crore, down from a loss of Rs 180.92 crore in H1FY26. Earnings Per Share (EPS) - Basic & Diluted: Basic and Diluted EPS stood at Rs 0.04 in Q2FY27, marking a full turnaround from a negative EPS of Rs 0.75 in Q2FY26 and a negative EPS of Rs 0.52 in Q1FY27. For H1FY27, Basic and Diluted EPS was negative at Rs 0.48, representing an improvement from a negative EPS of Rs 1.37 in H1FY26. Standalone Financial Highlights: Revenue from Operations: Standalone Revenue from Operations reached Rs 1,345.38 crore in Q2FY27, expanding by 19.35% YoY from Rs 1,127.26 crore in Q2FY26 and up 19.59% QoQ from Rs 1,124.95 crore in Q1FY27. For H1FY27, Revenue from Operations stood at Rs 2,470.33 crore, marking a 17.80% YoY growth over Rs 2,097.14 crore in H1FY26. Total Income: Standalone Total Income came in at Rs 1,483.31 crore in Q2FY27, showing a growth of 11.59% YoY against Rs 1,329.23 crore in Q2FY26 and a 19.66% QoQ growth against Rs 1,239.58 crore in Q1FY27. For H1FY27, Total Income stood at Rs 2,722.89 crore, showing a 9.79% YoY expansion relative to Rs 2,480.03 crore in H1FY26. Profit Before Tax (PBT): PBT stood at Rs 224.60 crore in Q2FY27, declining by 9.22% YoY compared to Rs 247.41 crore in Q2FY26 but expanding by 50.25% QoQ from Rs 149.48 crore in Q1FY27. For H1FY27, Standalone PBT was Rs 374.08 crore, representing a 4.08% YoY contraction from Rs 389.99 crore in H1FY26. Profit After Tax (PAT): PAT arrived at Rs 170.74 crore in Q2FY27, falling by 13.03% YoY from Rs 196.33 crore in Q2FY26 but gaining 50.46% QoQ from Rs 113.48 crore in Q1FY27. For H1FY27, PAT reached Rs 284.22 crore, which is an 8.16% YoY drop from Rs 309.47 crore in H1FY26. Earnings Per Share (EPS) - Basic: Basic EPS reached Rs 1.29 in Q2FY27, down 12.84% YoY from Rs 1.48 in Q2FY26 and up 51.76% QoQ from Rs 0.85 in Q1FY27. For H1FY27, Basic EPS stood at Rs 2.14, a drop of 8.55% YoY from Rs 2.34 in H1FY26. Nandini Piramal, Chairperson, Piramal Pharma, said: “We delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across our businesses, disciplined execution, and improved operating leverage. The performance was led by our CDMO business, which grew 28% on the back of strong order inflows and robust execution. Our CHG business complemented this momentum with 24% growth, supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, we are well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline.” Result PDF
PDF
VIEW ALL

Piramal Pharma DocumentsAsk MarketMind AI

Piramal Pharma Earnings Call

Piramal Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Oct 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
28 Oct 2026Piramal Pharma Results Earnings Call for Q2FY27AudioVideo
31 Jul 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
30 Jul 2026Piramal Pharma Results Earnings Call for Q1FY27AudioVideo
29 Apr 2026Piramal Pharma Results Earnings Call for Q4FY26AudioVideo
view all

Piramal Pharma Annual Reports

Piramal Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link

Piramal Pharma Credit Ratings

Piramal Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
16 Jul 2026care ratingsPiramal Pharma LimitedLink
14 Oct 2025icra ratingsPiramal Pharma LimitedRating withdrawnLink
17 Jul 2025care ratingsPiramal Pharma LimitedLink
05 Mar 2025care ratingsPiramal Pharma LimitedLink
21 Oct 2024icra ratingsPiramal Pharma Limited[ICRA]A1+; assignedLink

Piramal Pharma Investor Presentations

Piramal Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
27 Oct 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
29 Jul 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
28 Apr 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
28 Jan 2026Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Nov 2025Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Piramal Pharma - Company Profile

Piramal Pharma Management Structure

Piramal Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Herve BerdouChief Operating Officer-Mar 26
Mr. Stuart NeedlemanChief Commercial Officer,Chief(Patient Services)-Mar 26
Mr. Jeffrey HamptonPresident,Chief Operating Officer-Mar 26
Mr. Sai PonugotiChief Executive Officer(Consumer Healthcare Department)-Mar 26
Ms. Rashida NajmiChief Quality Officer-Mar 26
Mr. Jatin LalPresident(Merger & Acquisitions)-Mar 26
Mr. Sandeep RathodGeneral Manager-Mar 26
Ms. Puneet RajputChief Human Resources Officer(Human Resources)-Mar 26
Maneesh SharmaCompany Secretary,Compliance Officer-Mar 26
PETER D DEYOUNGExecutive Director,Chief Executive Officer-Mar 26
Vivek ValsarajExecutive Director,Chief Financial Officer-Mar 26

Piramal Pharma Board of Directors

Piramal Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
PETER D DEYOUNGExecutive Director & CEO850Mar 26
Nandini PiramalChairperson / Executive Director843Mar 26
Vivek ValsarajExecutive Director & CFO455Mar 26
Jairaj Manohar PurandareIndependent Non Exe. Director54Mar 26
Vibha Paul RishiIndependent Non Exe. Director50.5Mar 26
Sridhar GorthiIndependent Non Exe. Director49Mar 26
Peter StevensonIndependent Non Exe. Director47.5Mar 26
Nathalie LeitchIndependent Non Exe. Director46.5Mar 26
AMIT SONIIndependent Non Exe. Director7.01Mar 26
Amit JainNon-Exec & Non-Independent Dir-Mar 26
Maneesh SharmaCompany Sec. & Compli. Officer-Mar 26
Website: www.piramalpharma.com

About the company - Business Profile

Piramal Pharma Ltd. (PPL) is a global pharmaceutical entity providing end-to-end drug development and manufacturing solutions. The company operates through a diversified model across three main verticals: Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH). With a presence in over 100 countries and 17 development and manufacturing facilities across India, North America, and the UK/Europe, PPL maintains a significant position in regulated markets, which account for approximately 70% of its revenue.

Key Points

  • Key Facts: Originally part of Piramal Enterprises Limited (PEL), Piramal Pharma was incorporated in March 2020 and listed as an independent entity on the BSE and NSE on October 19, 2022. It is headquartered in Mumbai, India, and remains a key part of the Piramal Group conglomerate.
  • Operations and Resources: The company manages 17 global facilities. Its CDMO business, Piramal Pharma Solutions (PPS), handles over 140 molecules under development, with more than 30 in Phase III. The CHG business, Piramal Critical Care (PCC), is a leader in inhalation anesthesia.
  • Market Position: PPL holds the #1 rank in the US Sevoflurane market with a 45% market share and the #1 rank in the US Intrathecal Baclofen market with a 75% market share. Its consumer healthcare segment serves approximately 180,000 chemists and cosmetic shops in India.
  • Revenue Breakdown (FY2025):
    • By Business Segment: CDMO (58% of total revenue), Complex Hospital Generics (30%), and India Consumer Healthcare (12%).
    • By Geography (CDMO): North America (38%), Europe (27%), India (25%), and Others (10%).
    • By Geography (CHG): North America (56%), Europe (15%), Japan (10%), and India (4%).
  • Key Products and Services:
    • CDMO: Provides integrated services in discovery, development, and commercial manufacturing. Differentiated offerings include Antibody-Drug Conjugates (ADC), High Potency APIs (HPAPI), and sterile injectables.
    • CHG: Specializes in inhalation, injectable, and intrathecal anesthesia and pain management.
    • ICH: Features power brands like Saridon, Supradyn, i-pill, Lacto Calamine, and Tetmosol. Power brands have demonstrated a 21% CAGR between FY23 and FY25.
  • Partnerships and Subsidiaries:
    • Maintains a 49% stake in AbbVie Therapeutics India Private Limited, a leader in the Indian ophthalmology market, which reported FY2025 revenue of ₹494 Cr.
    • Holds a 33.33% strategic investment in Yapan Bio, specializing in biologics and vaccines.
    • The company has 21 subsidiaries, with 19 incorporated outside India.
  • Employee Base: Employs approximately 6,719 full-time staff globally, with 5,076 based in India and 1,643 internationally.
  • Strategic Initiatives and Outlook: Current focus is on expanding the Lexington and Riverview facilities in the US with a $90 million investment. Despite recent performance impacts from inventory destocking in a major on-patent commercial product, the company has observed a pick-up in Requests for Proposals (RFPs) since October 2025, signaling recovery in the CDMO order inflow.

References

  1. Annual Report May 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Piramal Pharma FAQ

Piramal Pharma today is trading in the green, up by 3.52% at ₹238.91.
Piramal Pharma is currently trading up 3.52% on an intraday basis. In the past week the stock rose 25.04%. Stock has been up 21.45% in the past quarter and rose 18.33% in the past year. You can view this in the share price history/seasonality section.
Piramal Pharma is listed on NSE with the ticker PPLPHARMA and on BSE as 543635. It's currently trading on NSE at a share price of ₹238.91 and on BSE with a share price of ₹239.05.
The market cap of Piramal Pharma is ₹31,807.24 Cr. as of Oct 30, 2026.
Piramal Pharma announced a FINAL dividend of 1.4% which equals ₹0.14 in Jul 16, 2025.The last ex-date for Piramal Pharma was Jul 12, 2024. To view the full dividend history of Piramal Pharma click here.
Piramal Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Piramal Pharma reported ₹2,652.99 Cr. in revenue, ₹5.58 Cr. in net profit, and ₹384.67 Cr. in EBITD as of Oct 27, 2026 for Q2 FY26-27.
According to the predictions of 11 analysts, the share price prediction for Piramal Pharma is ₹257.36 with an upside of 8%.
The PE ratio of Piramal Pharma is -152.32 as of Oct 30, 2026.
The PB ratio of Piramal Pharma is 3.94 as of Oct 30, 2026.
You can view the latest analyst reports on the Piramal Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×